ASTRAZENECA PLC |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12,135 GBX | -0.25% |
|
-1.86% | +14.53% |
| May. 16 | AstraZeneca's Sipavibart Prevents COVID-19 in Immunocompromised Patients in Phase 3 Trial | MT |
| May. 16 | Global markets live: Cisco, EasyJet, Roche, Netflix, Amazon... |  |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 239B | ||||||
| 694B | ||||||
| 593B | ||||||
| 371B | ||||||
| 331B | ||||||
| 290B |
- Stock Market
- Equities
- AZN Stock
- Charts AstraZeneca PLC
- Sector Chart
